Navigation Links
Savient Pharmaceuticals Announces Search for CEO
Date:12/28/2010

EAST BRUNSWICK, N.J., Dec. 28, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its Board of Directors has initiated a search for a Chief Executive Officer.  Paul Hamelin, Savient's President since November 2008 and its most senior executive officer, will continue to lead the day-to-day operations of the company until Savient hires a CEO.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

FORWARD LOOKING STATEMENTS

Any statements contained in this release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements regarding the search for a chief executive officer and the continuing role of Paul Hamelin are forward-looking statements.  All forward-looking statements rely on assumptions and are subject to various risks and uncertainties that could ca
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
4. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
5. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
6. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
7. Savient Pharmaceuticals To Hold First Quarter 2010 Results
8. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
11. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
(Date:9/1/2015)... ... September 01, 2015 , ... Specialty Technical Publishers (STP) ... Audit Protocol Consortium (IAPC) EHS audit protocol for the European Union. Leading companies ... their EHS regulatory obligations and rapidly collect, share, archive, and export audit findings ...
(Date:9/1/2015)... ... 2015 , ... Curly Hair Solutions™ is thrilled to partner ... partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution of ... Curly Hair Solutions™ team could not be more delighted to see their line ...
(Date:8/31/2015)... TN (PRWEB) , ... September 01, 2015 , ... The ... and other clinically relevant measures for physical therapy patients. The Registry is being developed ... of FOTO, Inc. stated "We are happy to be selected to contribute FOTO Outcomes ...
(Date:8/31/2015)... ... August 31, 2015 , ... Jvion, ... their latest predictive use case focused on helping hospital perform under the Center ... program, hospital payments are adjusted based on performance across four domains related to ...
(Date:8/31/2015)... ... , ... Cosmetic Town Journal is an online plastic surgery ... successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients and connecting ... help. , It is clear that the Cosmetic Town aesthetic surgery community has ...
Breaking Medicine News(10 mins):Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2
... Medical Center demonstrates that, for certain patient populations, an ... cost effective treatment. The implantable device, called Rheos, ... drug resistant hypertension. The study which ... Hypertension used data from two large population-based ...
... not so far-fetched, say scientists who now have possible ... -- Researchers have identified a potential target for drug ... cord scar tissue release molecules that prevent severed nerve ... connections that would restore feeling and movement. , In ...
... ... for the life science, engineering and entertainment industries, announced today they have signed an ... devices incorporating Microsoft’s SenseCam technology worldwide. , ... Oxford UK (PRWeb UK) October 15, 2009 -- Vicon, developer ...
... following is a statement of Matthew L. Myers, President, ... ) , A landmark report released today ... that elected officials have no excuse for failing to ... smoke-free laws reduce the number of heart attacks and ...
... finds sharp hikes in blood pressure when overweight, air pollution ... appears to hit the obese hardest, causing significant increases in ... been linked to a variety of health problems including asthma, ... obesity has been taken into account, researchers say. , "For ...
... the Slovenian capital, is hosting the EAU 9th Central ... 24 October. Professor Ciril Oblak (Ljubljana, SI) is chairman ... differences between Western European and Central European countries in ... dom Cultural and Congress Centre is this year,s CEM ...
Cached Medicine News:Health News:Cost effectiveness of blood pressure device evaluated 2Health News:Cost effectiveness of blood pressure device evaluated 3Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 2Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 3Health News:Institute of Medicine Report Concludes Smoke-Free Laws Prevent Heart Attacks; It's Time to Make All Workplaces and Public Places Smoke-Free 2Health News:Institute of Medicine Report Concludes Smoke-Free Laws Prevent Heart Attacks; It's Time to Make All Workplaces and Public Places Smoke-Free 3Health News:Smog Tougher on the Obese 2Health News:Smog Tougher on the Obese 3Health News:Ljubljana center of Europe during EAU 9th Central European meeting 2
... Splint is constructed of a durable heat moldable ... flexor tendons of the hand and fingers from ... in the later stages of the healing process. ... hand and positions the wrist at 30° of ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
... FoamWrap Finger Trappers are ideal for ... restore finger motion. Finger Trappers' non-slip foam ... place the fingers in traction. These are ... size. Sold in packages of 5 and ...
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
Medicine Products: